

Abstract Number: DI-004

Title

STUDY ON PRESCRIPTION PATTERN AND COST ANALYSIS OF ANTIRETROVIRAL DRUGS IN A TERTIARY CARE HOSPITAL.

Name *E. Molina¹, P. Nieto¹, J.M Ruiz-González¹, F. Verdejo¹, F. Sierra¹, D. Fernández¹.*

Address ¹Hospital Torrecárdenas, Hospital Pharmacy, Hermandad de los Donantes de Sangre s/n Almeria, Spain. PC 04009

Background

Antiretroviral therapy for treatment of human immunodeficiency virus type 1 (HIV-1) infection has improved steadily since the advent of combination therapy.

Objectives

To assess the prescription pattern and cost of antiretroviral therapy in a tertiary care hospital.

Study Design




Pharmacological therapies of HIV-1 were compared in adult patients affiliated with a tertiary care hospital of the Spanish Health System. All had been in treatment for more than six months (January-Jun 2014). The data were collected from medication consumption files of the institution. Annual cost data were calculated by multiplying the monthly up-to-date antiretroviral therapy cost for twelve.

RESULTS

604 patients were treated in this period using a total of 71 different combinations. The age range of patients was from 18 to 65 years and 73.01% were men. The total expenditure for the hospital was 4267561€ accounting for 16.77% of the whole budget in outpatient treatments. The average cost per patient was 7065€. The seven most common combinations (number of patients, %), their costs (€) and their economic impacts for the hospital among antiretroviral therapies (€, %) were: 1.-

- 1.- Emtricitabine/Tenofovir/Efavirenz (155, 25.66%), 5805€, (899794€, 21.08%),
- 2.- Emtricitabine/Tenofovir/Rilpivirine (64, 10.60%), 6723€, (430241€, 10.08%),
- 3.- Emtricitabine/Tenofovir + Lopinavir/Ritonavir (52, 8.61%), 8125€, (422523€, 9.90%),
- 4.- Emtricitabine/Tenofovir + Atazanavir/Ritonavir (48, 7.95%), 8629€, (414184€, 9.71%),
- 5.- Emtricitabine/Tenofovir + Darunavir/Ritonavir (28, 4.64%), 8617€, (241265€, 5.65%),
- 6.- Emtricitabine/Tenofovir + Nevirapina (25, 4.14%), 4489€, (112218€, 2.63%),
- 7.- Emtricitabine/Tenofovir + Raltegravir (22, 3.64%), 9263€, (203792€, 4.78%).

MOST FREQUENT COMBINATIONS, 81% OF TOTAL HOSPITAL EXPENDITURE 85,43% OF TOTAL PATIENT



CONCLUSION

✓ Despite the fact of the large variety of combinations used for HIV-1, Emtricitabine/Tenofovir/Efavirenz combo has been by far the most used. It is also one of the cheapest options among the most common therapies. These seven aforementioned options account for almost 64% of antiretroviral costs and cover 65% of the HIV-1 treatments. Additionally is highly remarkable that all of them have been Emtricitabine/Tenofovir-based therapies.

Acknowledgements

We thank Torrecardenas' s hospital pharmacists for their support

There is not any conflict of interest at all.

